NEW YORK, March 29 – Invitrogen said Thursday it has settled pending patent infringement suits against Promega and two other competitors, New England Biolabs and Display Systems Biotech, in which Invitrogen alleged that its competitors had infringed on its patents for modified reverse transcriptase enzymes with low RNase activity.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Wired reports that 23andMe is trying to bolster its outside collaborations.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.